Silence Therapeutics plc (SLN) stock
SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
$19.80+0.00 (0.00%)
Close on Nov 17, 2026Market cap $935.48MP/E –Yield –
Silence Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Silence Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$44.15M. For fiscal 2025 it was -$62.27M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$62.27M | – |
| FY2024 | Dec 31, 2024 | -$67.64M | – |
| FY2023 | Dec 31, 2023 | -$49.46M | – |
| FY2022 | Dec 31, 2022 | -$57.04M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$12.78M | – |
| Q2 FY2026 | Jun 30, 2026 | $1.52M | – |
| Q1 FY2026 | Mar 31, 2026 | -$15.60M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.29M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.78M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.31M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.48M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.61M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.41M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.14M | – |
See a number that looks wrong?